<DOC>
	<DOCNO>NCT00507585</DOCNO>
	<brief_summary>PRIMARY : - To determine toxicity tolerability intra-arterial hepatic oxaliplatin every three week administer combination systemic intravenous Fluorouracil , Leucovorin bevacizumab patient advance solid tumor metastatic liver . SECONDARY : - To document descriptive fashion antitumor efficacy combination regimen . - To evaluate feasibility accuracy alternate radiographic assessment tool compare available tumor marker RECIST guideline . - To estimate descriptive fashion development extrahepatic tumor recurrence .</brief_summary>
	<brief_title>Hepatic Arterial Infusion Oxaliplatin , Fluorouracil , Leucovorin , Avastin</brief_title>
	<detailed_description>Oxaliplatin design interfere growth cancer cell ( slow growth spread ) , eventually destroy . 5-fluorouracil design interfere growth cell reproduce rapidly . Leucovorin design strengthen effect 5-fluorouracil reduce tumor cell resistance 5-fluorouracil . Bevacizumab design interfere blood flow tumor , may cause tumor `` starve '' oxygen nutrient need grow . Before start study , `` screening test . '' These test help doctor decide eligible take part study . You complete medical history record physical exam , include measurement vital sign ( blood pressure , temperature , breathe rate , heart rate ) . You neurological evaluation ( test evaluate strength nerve function ) . You blood draw ( 1 teaspoon less ) urine collect routine test . Women able child must negative urine pregnancy test . If find eligible take part study , hospitalize receive study drug combination . On day admission hospital , catheter hepatic artery place right groin . After catheter place , receive study drug . The catheter place removed cycle . A catheter sterile flexible tube place large vein local anesthesia . Your physician explain procedure detail , require sign separate consent form procedure . You must lay bed entire time catheter place . In case , catheter remove immediately chemotherapy complete . In case , catheter may remain overnight . Therefore , must remain bed catheter remove . During cycle ( Days 1 2 ) , receive 5-fluorouracil vein continuously 24 hour , leucovorin vein 1 hour , oxaliplatin hepatic artery 2 hour , bevacizumab vein ( Day 1 ) 1 1/2 hour . This study drug combination repeat every 3 week , consider 1 cycle ( every 21 day ) . To learn high tolerable dose oxaliplatin give combination study drug , dose escalation process go follow . The dose oxaliplatin receive depend enrol study . The dose 3 study drug receive participant study . At first , 6 participant enrol first dose level oxaliplatin . If disease get worse intolerable side effect occur , another 6 patient enrol next high dose level . This dose escalation process continue way 8 dose level reach without intolerable side effect occur . You blood draw ( 2 teaspoon ) blood count liver function test dose study drug combination . This doctor check safety drug combination . You also blood drawn ( 2 teaspoon ) cycle . The doctor evaluate disease health receive study drug . Your tumor evaluate image scan ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) need type cancer . Imaging scan perform every 2 cycle . You may continue receive study drug combination indefinitely mention unless disease get bad experience intolerable side effect . If disease get bad experience intolerable side effect , remove study . If participation end reason study ( mention ) , image scan ( CT MRI ) see tumor grow shrink . You blood draw ( 3 teaspoon ) routine test . These end-of-study test perform regular doctor 's office , result send study 's research staff . This investigational study . Oxaliplatin authorize FDA systemic use . ( Systemic therapy affect body whole . ) Giving oxaliplatin directly liver investigational . 5-fluorouracil , leucovorin , bevacizumab FDA-approved treatment colorectal cancer . The use drug combination authorize FDA use research . Bevacizumab FDA-approved cancer type include study . Up 163 patient take part study . All patient enrol M. D. Anderson .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients histologically confirm metastatic advance solid tumor involve liver . 2 . Pediatric patient eligible discretion primary investigator . 3 . Performance status ECOG 02 ( Capable self care unable carry work activity ) . 4 . Adequate renal function ( Serum Creatinine &lt; /= 2.0 mg/dL ) calculate creatinine clearance great 60 mL/min . 5 . Hepatic function follow : In treatment arm 1 : Total Bilirubin &lt; /= 3 mg/dL , AST &lt; /= 5 time upper normal reference value , ALT &lt; /= 5 time upper normal reference value ) . In treatment arm 2 : Total bilirubin &gt; 3 mg/dL . If bilirubin &gt; /= 5 mg/dL , fluorouracil ( 5FU ) dose omit . 6 . Adequate bone marrow function ( ANC &gt; /=1500 cells/uL ; PLT &gt; /= 100,000 cells/uL ) . 7 . At least three week previous immunotherapy , chemotherapy radiotherapy day HAI infusion recovery associate toxicity less equal Grade 1 . 8 . All female childbearing age MUST negative serum HCG test unless prior hysterectomy menopause ( define age 55 six month without menstrual activity ) . Patients become pregnant breast feed study . Sexually active patient use effective birth control . 9 . Ability fully read , comprehend , sign inform consent form . 1 . Clinical radiographic evidence ascites . 2 . Pregnant female . 3 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 4 . Grade 2 Peripheral Neuropathy ( CTC V3.0 : Sensory alteration interfere function interfere ADL ) 5 . Serious nonhealing wound , ulcer bone fracture . 6 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day . 7 . Invasive procedure define follow ; Major surgical procedure , open biopsy significant traumatic injury within 28 day prior Day 1 therapy , Anticipation need major surgical procedure course study , Core biopsy within 7 day prior D1 therapy . 8 . Patients receive investigational agent . 9 . Patients bleed diathesis ( clinical bleeding , prothrombin time =/ &gt; 1.5 X upper institutional normal value , INR =/ &gt; 1.5 , activate partial thromboplastin time aPTT =/ &gt; 1.5 X upper institutional normal value ) , active gastric duodenal ulcer . 10 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , Diastolic Blood Pressure &gt; 90 mmHg ) . 11 . Urine protein screen dipstick urine analysis . For proteinuria &gt; 1+ urine protein : creatinine ratio &gt; 1.0 , 24hour urine protein obtain level &lt; 1000 mg patient enrollment . 12 . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 13 . Patients clinically significant cardiovascular disease : History CVA within 6 month , myocardial infarction unstable angina within 6 month , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication , unstable angina pectoris , clinically significant peripheral vascular disease 14 . Patients history bleed CNS metastasis exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Metastatic advance solid tumor</keyword>
	<keyword>Advanced solid tumor metastatic liver</keyword>
	<keyword>Hepatic Arterial Infusion</keyword>
	<keyword>Intra-arterial hepatic oxaliplatin</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>Adrucil</keyword>
	<keyword>Efudex</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>Avastin</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>